Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Duruisseaux · SciRah

Researcher profile · Semantic Scholar

M. Duruisseaux

Share profile

M. Duruisseaux — researcher profile on SciRah

h-index: 8
Works: 39
Citations: 177

Most-cited papers

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
F. Barlesi, Wen-Xiu Yao, M. Duruisseaux, L. Doucet +17 more
2025The Lancet64 citations
Semantic Scholar
COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitors
Augustin Boudoussier, Iban Larrouture, P. Henrot, R. Veillon +6 more
2025Scientific Reports12 citations Open access
Semantic Scholar
1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
A. Schram, K. Goto, D.-W. Kim, A. Hollebecque +16 more
2023Annals of Oncology12 citations Open access
Semantic Scholar
Lorlatinib: a new treatment option for ROS1-positive lung cancer.
M. Duruisseaux
2019The Lancet Oncology10 citations Open access
Semantic Scholar
MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients
E. Gobbini, A. Toffart, M. Pérol, J. Assié +24 more
2019Journal of Thoracic Oncology10 citations Open access
Semantic Scholar
1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
A. Schram, T. Macarulla, J. Cleary, C. Neuzillet +16 more
2023Annals of Oncology9 citations
Semantic Scholar
Serum total periostin is an independent marker of overall survival in bone metastases of lung adenocarcinoma
E. Massy, J. Rousseau, M. Gueye, E. Bonnelye +14 more
2021Journal of Bone Oncology9 citations Open access
Semantic Scholar
LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12
F. Barlesi, W. Yao, M. Duruisseaux, L. Doucet +14 more
2024Annals of Oncology8 citations
Semantic Scholar
Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Stephen V. Liu, M. Duruisseaux, K. Tolba, E. Brandén +15 more
2019Annals of Oncology7 citations Open access
Semantic Scholar
37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer
A. Chour, J. Denis, C. Lafitte, C. Mascaux +16 more
2022Annals of Oncology6 citations Open access
Semantic Scholar
Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy?
M. Duruisseaux, A. Mc Leer-Florin, D. Moro-Sibilot, J. Cadranel
2017Annals of Oncology6 citations Open access
Semantic Scholar
P1.14-25 Targeting NRG1-Fusions in Lung Adenocarcinoma: Afatinib as a Novel Potential Treatment Strategy
M. Duruisseaux, J. Laskin, K. Tolba, E. Brandén +11 more
2019Journal of Thoracic Oncology5 citations Open access
Semantic Scholar
OA09.06 Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
E. Felip, T. Mok, S. Lu, F. Barlesi +16 more
2024Journal of Thoracic Oncology4 citations
Semantic Scholar
NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib
Y. Goto, J. Cadranel, B. Weinberg, M. Duruisseaux +14 more
2019Annals of Oncology3 citations Open access
Semantic Scholar
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial
V. Gounant, L. Greillier, C. Mascaux, F. Pinquie +19 more
2025JTO Clinical and Research Reports2 citations Open access
Semantic Scholar
595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
D.-W. Kim, K. Goto, A. Schram, A. Hollebecque +16 more
2023Annals of Oncology2 citations
Semantic Scholar
P86.08 Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
A. Schram, T. Macarulla, E. O'Reilly, J. Rodón +17 more
20212 citations Open access
Semantic Scholar
MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC
S. Ou, L. Gandhi, A. Shaw, R. Govindan +17 more
20172 citations Open access
Semantic Scholar
3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort
J. Cadranel, E. Quoix, M. Duruisseaux, S. Friard +16 more
20152 citations
Semantic Scholar
1324P Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial
V. Gounant, L. Greillier, C. Mascaux, F. Pinquie +16 more
2024Annals of Oncology1 citations
Semantic Scholar
1369P BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
R. Descourt, F. Guisier, M. Perol, J. Cadranel +10 more
2023Annals of Oncology1 citations Open access
Semantic Scholar
193P Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstitial lung disease
C. Joseph, J. Mazières, M. Delaunay, A. Lusque +14 more
2022Annals of Oncology1 citations Open access
Semantic Scholar
34P RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions
A. Marinello, M. Duruisseaux, W. Zrafi, F. Dall'Olio +16 more
2022Annals of Oncology1 citations Open access
Semantic Scholar
1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
S. Baldacci, B. Besse, V. Avrillon, B. Mennecier +16 more
2020Annals of Oncology1 citations Open access
Semantic Scholar
OA01.02: Efficacy and Safety of Zenocutuzumab, a HER2/HER3 Bispecific Antibody, in Treatment-Naive, Advanced NRG1+ NSCLC: Updated Analysis from the Ongoing Phase 2 eNRGy Trial
Stephen V. Liu, Muskan Agarwal, Koichi Goto, K. Nishino +16 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
P2.102: Clinico-Biological Characteristics and Treatment Outcomes in Patients With RET+ Lung Cancer With non-LUAD Histology
A. Marinello, M. Lomibao, J. Quintanilha, T. Adeyelu +46 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
P2.348: A Phase 1b/2, Open-Label Study Evaluating Gocatamig and Ifinatamab Deruxtecan for Extensive-Stage Small-Cell Lung Cancer
M. Gutierrez, E. Schenk, K. Syrigos, J.-M. Sun +16 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
P3.18.60 The COALA (Cure Oncogene-Addicted Lung Adenocarcinoma) Network: A Nationwide Consortium to Improve Lung Cancer Outcome
J. Mazières, V. Albinet, O. Calvayrac, M. Alifano +17 more
2025Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
1828P Adjuvant alectinib versus platinum-based chemotherapy in resected stage IB–IIIA ALK+ NSCLC: A cost-effectiveness analysis in the French context
R. Supiot, A. Gherardi, L. Du Manoir De Juaye, O. Doghri +3 more
2025Annals of Oncology0 citations Open access
Semantic Scholar
1972P Modeling of pemetrexed maintenance de-escalation strategies using digital twins-based in silico clinical trials in FLAURA2 regimen as front-line treatment of metastatic EGFR-mutated non-small cell lung cancer
M. Duruisseaux, A. Nativel, P. Masson, N. Girard +11 more
2025Annals of Oncology0 citations Open access
Semantic Scholar
1987MO Efficacy of lorlatinib after failure of a first-line ROS1 tyrosine kinase inhibitor (ROS1 TKI) in patients (pts) with advanced ROS1-positive non-small cell lung cancer (ROS1+ NSCLC) (IFCT-2003 ALBATROS)
M. Duruisseaux, C. Ardin, C. Mascaux, F. Bigot +14 more
2025Annals of Oncology0 citations Open access
Semantic Scholar
1294P Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry
A. Marinello, G. Massa, J. Rotow, H. B. de Cabo +16 more
2024Annals of Oncology0 citations
Semantic Scholar
2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
J. Mazières, M. Duruisseaux, H. Curcio, C. Morizane +7 more
2023Annals of Oncology0 citations
Semantic Scholar
121P Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
A. Brindel, T. Anne-Claire, J. Praz, S. Cousin +6 more
2023ESMO Open0 citations Open access
Semantic Scholar
P25.01 Efficacy of Weekly Paclitaxel-Bevacizumab Combination in Advanced NSCLC: AVATAX, A Retrospective Multicentric Study
G. Bilger, A. Toffart, M. Darrason, M. Duruisseaux +16 more
2021Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
N. Girard, S. Girodet, M. Duruisseaux, V. Avrillon +16 more
20200 citations Open access
Semantic Scholar
Immune checkpoint inhibitors (ICPis) re-challenge : outcomes analysisin a french national cohortof non small cell lung cancer (NSCLC) patients.
E. Gobbini, M. G. Levra, M. Pérol, C. Chouaid +24 more
20190 citations
Semantic Scholar
P2.01-96 Response to Anti-HER2 Afatinib in a Case of Invasive Pulmonary Mucinous Adenocarcinoma with a SLC3A2-NRG1 Fusion
F. Magne, V. Haddad, L. Odier, M. Duruisseaux +4 more
2019Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
P2.03b-037 Prognostic Impact of 1st-Line Treatment and Molecular Testing in Advanced NSCLC in France - Results of the IFCT-PREDICT.amm Study: Topic: Biomarkers
J. Cadranel, E. Quoix, M. Duruisseaux, S. Friard +19 more
20170 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Cadranel×8
Invite
J. Cadranel — researcher profile on SciRah
A. Drilon×6
Invite
A. Drilon — researcher profile on SciRah
V. Westeel×6
Invite
V. Westeel — researcher profile on SciRah
F. Guisier×5
Invite
F. Guisier — researcher profile on SciRah

×5

Invite

É. Dansin — researcher profile on SciRah

C. Decroisette×5

Invite

C. Decroisette — researcher profile on SciRah

Invite

N. Girard — researcher profile on SciRah

Invite

A. Swalduz — researcher profile on SciRah

D. Moro-Sibilot×5

Invite

D. Moro-Sibilot — researcher profile on SciRah

J. Raimbourg×5

Invite

J. Raimbourg — researcher profile on SciRah

J. Mazières×5

Invite

J. Mazières — researcher profile on SciRah

Invite

B. Besse — researcher profile on SciRah